BACKGROUND Patients with atrial fibrillation (AF) and $1 point on the stroke risk scheme CHA 2 DS 2 -VASc (congestive
stratification. Points are given for these various factors (6) . For low-risk patients with a score of 1 on the CHA 2 DS 2 -VASc, the European Society of Cardiology recommends treatment with either an adjusted-dose vitamin K antagonist (e.g., warfarin) or, preferably, 1 of the new OAC agents (i.e., dabigatran, rivaroxaban, apixaban). However, stroke risk estimates for AF patients with a CHA 2 DS 2 -VASc score of 1 and no OAC treatment varies by a factor of 3 among different studies, from 0.6% to >2.0% (6) (7) (8) (9) (10) (11) (12) (13) . At an annual unprotected risk of 0.6%, it is unlikely that patients will realize the benefits of treatment, whereas patients with an annual risk >1% are more likely to benefit from treatment (14) (15) (16) .
The goal of the present study was to assess the risk of AF-related stroke among patients without OAC treatment and a CHA 2 DS 2 -VASc score of 1.
METHODS
This was a retrospective study of unselected patients Table 1 . The index date was defined by first contact with a diagnosis of AF in the National Patient Register during the study period. Follow-up lasted until the specified event, death, or July 1, 2010, whichever came first.
Stroke events during follow-up were identified in the National Patient Register, which was crossmatched with the Swedish national stroke register (known as Riks-Stroke). We evaluated how the estimated event rates were affected by the various ways of counting these events that were used in previous studies. We thus investigated how much the estimate of the annual "stroke" rate was affected by the inclusion of other diagnoses such as TIA or pulmonary embolism, as in some of the earlier studies ( Table 1) .
We also evaluated how varying degrees of inclusiveness in the counting of secondary diagnoses affected the estimate, under the assumption that a low secondary diagnosis of acute ischemic stroke has lower validity than one given as a principal diagnosis.
Last, we examined how the estimated annual stroke risk was affected by quarantine periods of varying lengths. Quarantine periods are commonly used in registry studies and consist of initial blanking periods after the index AF diagnosis, postponing the counting of days at risk. During this period, no events or deaths are counted. Because patients can only be identified as AF patients when they seek medical care, there will be patients who do not primarily seek medical attention due to AF but do so because of unrelated acute disease. Some of these patients may have done so because of acute stroke, myocardial infarction, imminent death, or some other reason not directly related to AF. If such patients also receive a secondary diagnosis of AF, they will enter the study, and their stroke, myocardial infarction, or death will be attributed to AF. If no blanking period is used, this classification would lead to overestimation of the risks associated with AF. To assess true long-term risks, it is therefore essential to ensure that the study population is stable when the observation period starts. Similar run-in periods are common in clinical drug trials in which it is essential to ascertain that there is no selection bias associated with patient recruitment.
Another reason for using a quarantine period is that acute stroke diagnoses are used in conjunction with transfers between clinics during the first days or (19, 20) . Warfarin use at baseline was defined as any purchase of warfarin later than 6 months before and up to 28 days after the index date.
Cross-matching of data in these registers was made by the National Board of Health and Welfare according to unique civic registration numbers that are given to all residents in Sweden, irrespective of citizenship. Before data were made available to us, these numbers were replaced by anonymized numbers to assure participants' personal integrity. Values are percent of events per year. *Diagnosis not applicable.
Abbreviation as in Table 1 .
Anticoagulation at a CHA 2 DS 2 -VASc Score of 1 6 months before the index date or during the study period (n ¼ 144,111) were excluded from further study. Thus, a total of 140,420 patients were included in the main analysis.
DURATION OF QUARANTINE PERIOD. The overall ischemic stroke event rate, as diagnosed by RiksStroke, was 5.4% if no quarantine period was used, 3.0% with a quarantine period of 1 week, and 2.8%
with a 4-week quarantine period ( Table 2 ). The overall rates were slightly higher if the National Patient
Register was used for event detection rather than Riks-Stroke, but the effects of quarantine periods on rates were similar. After w4 weeks, event rates had stabilized at a level almost one-half as high as if no quarantine period had been used ( Figure 1 ). For the purposes of reporting our results, the 4-week quarantine period was chosen as the most representative for long-term stroke risk beyond the first month.
When a diagnosis of ischemic stroke (I63) was used in the National Patient Register, it was placed as the principal diagnosis in 82% of the cases. Using both the principal and the first secondary diagnoses to identify patients with ischemic stroke classified 90% of cases.
A minority had the diagnosis placed far down among the secondary diagnoses; the maximum was a patient with ischemic stroke as the 13th diagnosis. In these cases, circumstances indicated that the appropriate ICD-10 code should have been I69 for sequelae of old stroke, rather than I63 for acute ischemic stroke 
DISCUSSION
The risk of ischemic stroke among patients with AF and a CHA 2 DS 2 -VASc score of 1 seems to be lower than previous studies have indicated. This earlier finding may have led to unnecessary, and potentially harmful, OAC treatment of low-risk patients.
The present study found that diverging estimates of stroke risks associated with AF are partly due to differences in study methods. Although event rates in previous studies generally are thought of as describing stroke risk, the figures actually represent much more diverse endpoints. Several of the studies included pulmonary embolism in the "stroke" endpoint (6,8-10) and some included TIAs (9,13). We do not agree on the inclusion of pulmonary Primary prevention of pulmonary embolism among patients with AF has, to the best of our knowledge, not been studied and is not an approved indication for OAC treatment.
We also did not find it relevant to count TIA as an endpoint in studies that describe stroke risk. In the Swedish National Patient Register, annual event rates varied depending on whether only ischemic strokes were counted (yellow bars) or additional factors were included. For patients with a CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/transient ischemic attack [TIA] , vascular disease, age 65-74 years, sex category) score of 1, the low annual event rates, varying between 0.5% and 0.9%, call into question the need for or use of oral anticoagulation therapy in these low-risk patients. The entries in parentheses are the International Classification of Diseases-10th Revision Code or Swedish Procedure Code.
however, a lack of quarantine periods will result in higher risk estimates than would be the case after the first few weeks. It is the long-term risk that is relevant for decisions regarding anticoagulation.
The extreme estimates of stroke risk in the Danish registry study (8) are difficult to explain; the 2.01% risk at a CHA 2 DS 2 -VASc score of 1 is 2 or 3 times higher than other studies (6, 7, (9) (10) (11) (12) . However, these
figures have been extensively used as a reference and thus have exerted considerable influence on the European decision to recommend treatment to patients with CHA 2 DS 2 -VASc scores of 1. Even when we include pulmonary embolism in the endpoint (which we oppose), our estimates only reach an annual risk of 0.7% (Central Illustration). In the Danish study, a quarantine period of 7 days was used, which may have increased the estimates. The Danish study also seems to have identified thromboembolic events from secondary diagnoses in any position, whereas in the main analysis, we used only the principal and first secondary diagnoses to avoid the common confusion in which patients with sequelae of stroke (code I69)
incorrectly receive codes for acute stroke (I63 or I64).
The Danish study also reported much lower prevalence of heart failure and diabetes (about one-half of that in the present study); these findings suggest that the Danish patients may have been given risk scores that were too low.
With an annual stroke risk of 2.0%, as in the Danish study (8) , anticoagulant treatment is expected to be of benefit, unless the bleeding risk is extreme (14-16).
In a study of the net benefit of OAC treatment in AF, Eckman et al. (24) found that an annual stroke risk of Nevertheless, the present study is twice as big as the largest study conducted thus far (8) and >100 times larger than the original CHA 2 DS 2 -VASc study (6) .
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